You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 154 No. 7, 11 April 1994 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Possible Nafcillin-Warfarin Interaction

Greta M. Heilker, PharmD; John W. Fowler, Jr, MD; Timothy H. Self, PharmD
Memphis, Tenn

Arch Intern Med. 1994;154(7):822-824.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

There are multiple reports of drug interactions with warfarin in the literature. Many of these result in resistance to warfarin therapy due to enzyme inducers such as barbiturates, carbamazepine, and rifampin, with resulting decreased warfarin effect and prothrombin time (PT).1-3 Nafcillin is not well documented as an inducer of drug metabolizing enzymes, yet it appears to have this effect on warfarin.4 We recently observed a possible interaction between nafcillin and warfarin.

Report of a Case.

A 71-year-old woman was admitted with a 3-month history of left lower extremity swelling and a 3-week history of pain, tenderness, and edema. On admission, an attempted left lower leg ultrasound was unsuccessful due to swelling of the lower leg. Therefore, her admitting diagnosis was rule-out deep vein thrombosis vs cellulitis of the lower leg. Her medicines prior to admission included levothyroxine (0.125 µg daily), extended-release nifedipine (60 mg twice daily), extended-release potassium . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.